Reducing the toxicity of amphotericin B by encapsulation using methoxy poly(ethylene glycol)-b-poly(l-glutamic
Chenguang Yang1, Baiji Xue, Wantong Song
1Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China. ztang@ciac.ac.cn.
Abstract:
Amphotericin B (AmB) is an antifungal drug used for serious fungal infections and leishmaniosis. However, its clinical application is limited because of its high toxicity. To resolve this problem, herein we loaded AmB into methoxy poly(ethylene glycol)-b-poly(l-glutamic acid-co-l-phenylalanine) (mPEG-b-P(Glu-co-Phe)) nanoparticles (l-AmB) via electrostatic, hydrophobic and π-π interactions. The l-AmB has excellent stability both in PBS and in plasma and shows a remarkably reduced hemolysis (17.1 ± 1.5%, 6 h) compared to the free AmB (94.2 ± 5.3%, 6 h). The nephrotoxicity of l-AmB is significantly lower than that of free AmB. The maximum tolerance dose (MTD) of l-AmB is 3.0 mg kg-1, which is 3.75 fold that of free AmB (MTD = 0.8 mg kg-1). The antimicrobial activity of the conjugate was retained in vivo, with l-AmB proving to be a more protective treatment for Aspergillus fumigatus infections in mice than AmB alone. These indicate that l-AmB is a formulation of AmB with low side effects.
Insights
This study developed a new nanoparticle formulation of Amphotericin B (AmB) to reduce its toxicity. The new formulation, l-AmB, demonstrated significantly lower side effects and improved therapeutic efficacy against fungal infections compared to free AmB.
Area of Science:
- Nanomedicine
- Pharmacology
- Biochemistry
Background:
- Amphotericin B (AmB) is a critical antifungal agent for severe infections.
- High toxicity limits the clinical use of Amphotericin B.
- Developing safer AmB formulations is crucial for effective treatment.
Purpose of the Study:
- To develop a novel nanoparticle formulation of Amphotericin B (AmB).
- To reduce the toxicity and improve the therapeutic index of AmB.
- To evaluate the stability, safety, and efficacy of the new AmB formulation.
Main Methods:
- Encapsulation of AmB into mPEG-b-P(Glu-co-Phe) nanoparticles (l-AmB).
- Assessment of nanoparticle stability in PBS and plasma.
- Evaluation of hemolysis, nephrotoxicity, and maximum tolerance dose (MTD).
- In vivo efficacy testing against Aspergillus fumigatus infections in mice.
Main Results:
- l-AmB nanoparticles exhibited excellent stability.
- Significantly reduced hemolysis (17.1%) compared to free AmB (94.2%).
- l-AmB showed substantially lower nephrotoxicity and a 3.75-fold higher MTD than free AmB.
- l-AmB retained antimicrobial activity and provided superior protection against fungal infections in mice.
Conclusions:
- The developed l-AmB nanoparticle formulation effectively reduces AmB toxicity.
- l-AmB offers improved safety and enhanced therapeutic efficacy.
- This formulation represents a promising strategy for treating serious fungal infections with reduced side effects.
More Related Videos
11:08Generation of Size-controlled Poly ethylene Glycol Diacrylate Droplets via Semi-3-Dimensional Flow Focusing Microfluidic Devices
Published on: July 3, 2018
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Related Concept Videos
Amino acids
Antiepileptic Drugs: Glutamate Antagonists
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Mixtures of Acids
A Mixture of a Strong Acid and a Weak Acid
In a mixture of a strong acid and a weak acid, the strong acid dissociates completely and becomes a source of almost all the hydronium ions...
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
